Skandinaviska Enskilda Banken (SEB)
LGND icon

Skandinaviska Enskilda Banken (SEB)’s Ligand Pharmaceuticals LGND Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,000
Closed -$1.29M – 877
2023
Q4 		$1.29M Hold
18,000
– – 0.01% 656
2023
Q3 		$1.08M Buy
18,000
+1,400
+8% +$92.1K 0.01% 671
2023
Q2 		$1.2M Sell
16,600
-6,000
-27% -$450K 0.01% 673
2023
Q1 		$1.66M Buy
+22,600
New +$1.61M 0.01% 591

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s LGND Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 18,000 shares — an estimated $1.29M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in LGND in Q1 2023 and held it in 4 quarters. The position peaked at $1.66M in Q1 2023. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 18,000 Ligand Pharmaceuticals shares in Q1 2024, an estimated $1.29M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Ligand Pharmaceuticals position peaked at $1.66M in Q1 2023.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.